[5] In July 2002, the Allergan ophthalmic surgical and contact lens care businesses were spun-off to create a new company, Advanced Medical Optics.

[9] In November 2014, Actavis announced its intention to acquire Allergan, Inc., the manufacturer of Botox[10] Completion of the deal would increase its market capitalization to $147 billion.

[14] On April 22, 2014, details were released by Valeant Pharmaceuticals and hedge fund CEO, Bill Ackman, about a $46 billion (CAD) offer presented to Allergan.

This bid was rejected by Allergan as being too risky, claiming Valeant's business model of serial acquisitions and low organic growth being unsustainable.

[20] In the afternoon of August 27, Bloomberg reported that Valeant and Pershing Square had won their case with the Chancery Judge setting an October 6 date for the aforementioned trial.

[21] On November 17, 2014, Actavis, plc announced it would acquire Allergan in a white knight bid for approximately $66 billion, putting an end to Valeant's hostile takeover attempt.